NCT03588598Unknown1 期
A Phase I Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Relapsed or Refractory Indolent B-Cell Hematologic Malignancies.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Time to Peak Plasma Concentration（Tmax）
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
详细描述
This is a phase I, sequential dose escalation followed by cohort expansion study of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory indolent B-cell hematologic malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.18- 75 years of age.
- •2.Histologically or cytologically confirmed diagnosis of relapsed or refractory indolent B-cell hematologic malignancies, including but not limited to CLL / SLL, FL (grade 1, 2 or 3a), or MZL.
- •3.Patients have received at least 1 prior regimen (at least 2 cycles).
- •4.Eastern Cooperative Oncology Group (ECOG) performance score of 0-
- •5.Life expectancy ≥ 3 months.
- •6.Patients have at least 1 measurable lesion that measures ≥1.5 cm in a single dimension as assessed by CT or MRI.
- •7.Adequate organ function, as defined by the following values: ANC≥1.0×10^9/L； PLT≥50×10^9/L； Hb≥80 g/L； TBIL≤1.5×ULN； ALT and AST≤2.5×ULN； BUN and Cr≤1.5×ULN； LVEF≥50%； QTcF <450 ms for male, QTcF <470 ms for female；
- •8.Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose, and female subjects of childbearing potential have a negative pregnancy test at baseline.
- •9.Subjects did not participate in other clinical trials within 3 months prior to study entry.
排除标准
- •Disease progression after previous treatment with any PI3Kδ inhibitors.
- •Had any other anti-tumor treatment within 4 weeks prior to screening (including radiotherapy, chemotherapy, hormone therapy, surgery or targeted therapy).
- •Evidence of central nervous system involvement of the malignancy.
- •Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, uncontrolled pleural effusion and ascites, uncontrolled diabetes, non-infectious pneumonia, and any other severe cardiovascular, respiratory, nervous and mental diseases.
- •Any of the severe heart diseases, including New York Heart Association (NYHA) Class II or greater heart failure, arrhythmias requiring medical treatment, and history of myocardial infarction or unstable angina within 6 months prior to screening.
- •Require any concomitant medication known to prolong the QT interval during the study.
- •Evidence of active bacterial, fungal, or viral infection.
- •Active infection with hepatitis B virus (HBV) (HBsAg positive, or HBsAg negative and HBV-DNA positive), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- •Use of high-dose glucocorticoids (eg, ≥20 mg/day prednisone) or other immunosuppressants within 4 weeks prior to study entry.
- •Concomitant use of any strong inhibitors or inducers of CYP3A
- •Use of G-CSF or blood transfusion within 7 days before the hematology test at screening.
- •Prior autologous hematopoietic stem cell transplantation within 6 months prior to treatment initiation.
- •History of prior allogeneic hematopoietic stem cell transplantation.
- •Major surgery within 4 weeks prior to treatment initiation.
- •History of a non-lymphoma malignancy in the past five years except for the following: adequately treated cervical carcinoma in situ, local basal cell or squamous cell carcinoma of the skin.
- •Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the drug or previous significant bowel resection that would preclude adequate absorption of the study drug.
- •History of hypersensitivity to drugs similar to the study drug or inactive excipients of the study drug.
- •Women who are breastfeeding.
研究组 & 干预措施
SHC014748M treatment
Experimental
SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
干预措施: SHC014748M (Drug)
结局指标
主要结局
Time to Peak Plasma Concentration（Tmax）
时间窗: 1 month
Area Under the Plasma Concentration Versus Time Curve (AUC)
时间窗: 1 month
Dose Limiting Toxicity (DLT)
时间窗: 1 month
Peak Plasma Concentration (Cmax)
时间窗: 1 month
Half-life Time(t1/2)
时间窗: 1 month
次要结局
- Time to Response (TTR)(up to 12 months)
- Lymph Node Response (LNR)(up to 12 months)
- Objective Response Rate (ORR)(up to 12 months)
- Progression-Free Survival (PFS)(up to 12 months)
- Duration of Response (DOR)(up to 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.Advanced Solid TumorsNCT05867420AskGene Pharma, Inc.594
已完成
1 期
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid MalignancySolid TumorMetastatic CancerNCT02412462Alethia Biotherapeutics15
已完成
1 期
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRelapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)NCT03787498Opna Bio LLC22
已完成
1 期
A Study of PLX2853 in Advanced Malignancies.Uveal MelanomaNon-Hodgkin LymphomaAdvanced MalignanciesSolid TumorDiffuse Large B Cell LymphomaSmall Cell Lung CancerFollicular LymphomaOvarian Clear Cell CarcinomaNCT03297424Opna Bio LLC49
已完成
1 期
A Phase I Study of SHR -2001 in Healthy SubjectsHealthyNCT05942612Guangdong Hengrui Pharmaceutical Co., Ltd72